Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial.
Elise van MulligenSterre S BourLucas M A GoossensPascal Hendrik Pieter de JongMaureen P M H Rutten-van MölkenAnnette H M van der Helm van MilPublished in: Annals of the rheumatic diseases (2024)
A fixed treatment course in individuals with arthralgia at-risk for RA and MRI-detected subclinical joint inflammation resulted in better work productivity, lower healthcare costs and improved quality of life over the course of 2 years; with the largest gain in productivity costs. This is the first evidence that methotrexate treatment aiming at secondary prevention in arthralgia at-risk for RA is cost-effective.
Keyphrases
- rheumatoid arthritis
- healthcare
- clinical trial
- placebo controlled
- study protocol
- climate change
- disease activity
- high dose
- double blind
- open label
- phase ii
- phase iii
- ankylosing spondylitis
- computed tomography
- squamous cell carcinoma
- randomized controlled trial
- low dose
- social media
- systemic sclerosis
- health information